Integra LifeSciences (NASDAQ:IART) Releases Q2 2023 Earnings Guidance

Integra LifeSciences (NASDAQ:IART – Get Rating) issued an update on its second quarter 2023 earnings guidance on Thursday morning. The company provided EPS guidance of $0.75-$0.79 for the period, compared to the consensus EPS estimate of $0.85. The company issued revenue guidance of $396.00 million-$400.00 million, compared to the consensus revenue estimate of $404.78 million. […]

Related Keywords

Lisa Evoli ,Integra Lifesciences ,Michaelj Mcbreen ,Citigroup ,Balyasny Asset Management ,Vanguard Group Inc ,Morgan Stanley ,Securities Exchange Commission ,Equity Group ,Integra Lifesciences Company Profile ,Integra Lifesciences Holdings Corp ,Norges Bank ,Get Rating ,Truist Financial ,Exchange Commission ,Asset Management ,Vanguard Group ,Lifesciences Holdings ,Codman Specialty Surgical ,Tissue Technologies ,Integra Lifesciences Daily ,Nasdaq Iart ,Tiart ,Medical ,45798520 ,Guidance ,Earnings ,Preannouncement ,